Compare Amylx Pharmaceuticals Inc (AMLX) vs Hyatt Hotels Corporation (H) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Hyatt Hotels Corporation — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Hyatt Hotels Corporation trades at $190.5 (market cap $18.00B). The key difference: Hyatt Hotels Corporation is far larger — about 9.1× Amylx Pharmaceuticals Inc's market cap, and Hyatt Hotels Corporation pays a 0.31% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | H | |
|---|---|---|
Market Cap | $1.98B | $18.00B |
Sector | Health | Consumer Cyclical |
52-Week High | $18.70 | $202.09 |
52-Week Low | $7.64 | $135.01 |
Enterprise Value | $1.70B | $21.84B |
Dividend Yield | — | 0.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Hyatt Hotels Corp (H) trades at $191.14, up 0.63% on the day, with a bearish technical signal but mixed earnings performance. Recent quarters show beats on EPS estimates, though net income margin remains negative at -0.48%. The company announced expansion plans, including a new Hyatt Regency in Tucson, amid stable revenue around $7.1B. Cash flow trends indicate operational challenges, with net cash flow turning negative in 2025.
Outlook is cautious with analyst consensus tilted toward Hold (52.08%). Upside exists if operational efficiency improves and travel demand sustains, but risks include high debt levels and profitability pressures. The stock trades near the consensus price target of $197.30, suggesting limited near-term upside without fundamental catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →
